Merestinib(Merestinib) - 药物靶点：AXL x NTRK x ROS1 x TYRO3 x Tie-2 x c-Met_在研适应症：晚期胆道癌，晚期癌症，HER2 阴性乳腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Merestinib (USAN/INN)

靶点

AXL x NTRK x ROS1 x TYRO3 x Tie-2 x c-Met

作用机制

AXL抑制剂(AXL受体酪氨酸激酶抑制剂)、NTRK抑制剂(神经酪氨酸激酶受体抑制剂)、ROS1抑制剂(原癌基因酪氨酸蛋白激酶ROS抑制剂)

+ [3]

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症

晚期胆道癌晚期癌症HER2 阴性乳腺癌+ [3]

非在研适应症

成人急性髓性白血病胆管癌骨转移癌+ [5]

原研机构

Eli Lilly & Co.

在研机构

Eli Lilly & Co.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评特殊审批 (中国)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C30H22F2N6O3

InChIKeyQHADVLVFMKEIIP-UHFFFAOYSA-N

CAS号1206799-15-6

关联

11

项与 Merestinib 相关的临床试验

NCT03292536 / Terminated临床1期IIT

An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer

This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.

开始日期2018-01-11

申办/合作机构

University of Utah

[+1]

NCT03125239 / Completed临床1期IIT

A Phase 1 Study of Merestinib in Combination With LY2874455 in Relapsed or Refractory Acute Myeloid Leukemia

This research study is studying a combination of two targeted therapies as a possible treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did not fully respond.
The name of the study interventions involved in this study are:
Merestinib
LY2874455

开始日期2017-08-10

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

NCT03027284 / Completed临床1期

A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.

开始日期2017-02-03

申办/合作机构

Eli Lilly & Co.

100 项与 Merestinib 相关的临床结果

登录后查看更多信息

100 项与 Merestinib 相关的转化医学

登录后查看更多信息

100 项与 Merestinib 相关的专利（医药）

登录后查看更多信息

24

项与 Merestinib 相关的文献（医药）

2023-03-01·Clinical Cancer Research

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

Article

作者: de Jonge, Adrienne ; DeAngelo, Daniel J. ; Tošić, Isidora ; Garcia, Jacqueline S. ; Galinsky, Ilene ; Wadleigh, Martha ; Neuberg, Donna ; Luskin, Marlise R. ; Pozdnyakova, Olga ; Stone, Richard M. ; Chen, Evan C. ; Leonard, Rebecca ; O'Day, Kelsey ; Fell, Geoffrey G. ; Frank, David A. ; Gandler, Helen ; Fiore, Ashlee ; Look, A. Thomas ; Winer, Eric S.

AbstractPurpose:Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have poor outcomes and require new therapies. In AML, autocrine production of hepatocyte growth factor (HGF) drives MET signaling that promotes myeloblast growth and survival, making MET an attractive therapeutic target. MET inhibition exhibits activity in AML preclinical studies, but HGF upregulation by the FGFR pathway is a common mechanism of resistance.Patients and Methods:We performed preclinical studies followed by a Phase I trial to investigate the safety and biological activity of the MET inhibitor merestinib in combination with the FGFR inhibitor LY2874455 for patients with R/R AML. Study Cohort 1 underwent a safety lead-in to determine a tolerable dose of single-agent merestinib. In Cohort 2, dose-escalation of merestinib and LY2874455 was performed following a 3+3 design. Correlative studies were conducted.Results:The primary dose-limiting toxicity (DLT) observed for merestinib alone or with LY2874455 was reversible grade 3 transaminase elevation, occurring in 2 of 16 patients. Eight patients had stable disease and one achieved complete remission (CR) without measurable residual disease. Although the MTD of combination therapy could not be determined due to drug supply discontinuation, single-agent merestinib administered at 80 mg daily was safe and biologically active. Correlative studies showed therapeutic plasma levels of merestinib, on-target attenuation of MET signaling in leukemic blood, and increased HGF expression in bone marrow aspirate samples of refractory disease.Conclusions:We provide prospective, preliminary evidence that MET and FGFR are biologically active and safely targetable pathways in AML.

2022-12-01·Journal of Hematology & Oncology

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Article

作者: Shimoji, Masaki ; Fujino, Toshio ; Hamada, Akira ; Ohara, Shuta ; Suda, Kenichi ; Soh, Junichi ; Takemoto, Toshiki ; Chiba, Masato ; Koga, Takamasa ; Mitsudomi, Tetsuya

AbstractBackgroundCapmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D1228X or Y1230X secondary mutations of the MET. In this study, we explored agents that are active against both D1228X and Y1230X MET to propose an ideal sequential treatment after capmatinib/tepotinib treatment failure in NSCLC patients with METex14.MethodsThe inhibitory effects of 300 drugs, including 33 MET-TKIs, were screened in Ba/F3 cells carrying METex14 plus MET D1228A/Y secondary mutations. The screen revealed four-candidate type II MET-TKIs (altiratinib, CEP-40783, foretinib and sitravatinib). Therefore, we performed further growth inhibitory assays using these four MET-TKIs plus cabozantinib and merestinib in Ba/F3 cells carrying MET D1228A/E/G/H/N/V/Y or Y1230C/D/H/N/S secondary mutations. We also performed analyses using Hs746t cell models carrying METex14 (with mutant allele amplification) with/without D1228X or Y1230X in vitro and in vivo to confirm the findings. Furthermore, molecular dynamics (MD) simulations were carried out to examine differences in binding between type II MET-TKIs.ResultsAll 6 type II MET-TKIs were active against Y1230X secondary mutations. However, among these 6 agents, only foretinib showed potent activity against D1228X secondary mutations of the MET in the Ba/F3 cell and Hs746t in vitro model and Hs746t in vivo model, and CEP-40783 and altiratinib demonstrated some activity. MD analysis suggested that the long tail of foretinib plays an important role in binding D1228X MET through interaction with a residue at the solvent front (G1163). Tertiary G1163X mutations, together with L1195F/I and F1200I/L, occurred as acquired resistance mechanisms to the second-line treatment foretinib in Ba/F3 cell models.ConclusionsThe type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230.

2022-09-09·BioMed Research International

Comparison of Different First-Line Systemic Therapies in Advanced Biliary Tract Cancer Based on Updated Random Controlled Trials: A Systematic Review and Network Meta-Analysis

Review

作者: Yi, Fengming ; Xu, Haoqian ; Feng, Long ; Wang, Ying

Background and Aim. The prognosis of advanced biliary tract cancer (BTC) is relatively poor, with limited survival. Currently, the first-line standard of care treatment is gemcitabine plus cisplatin, whereas numerous trials are trying to explore new regimens and prolong the life span of these patients. Herein, we aim to compare the effectiveness of different treatments and conclude more promising regimens for patients with advanced BTC. Methods. We searched PubMed, Web of Science, and Cochrane Library for abstracts and full-text articles published from database inception through May 2022. All the random controlled trials (RCTs) were assessed and collected as eligible studies. The primary outcome was overall survival (OS). The second outcome was progression-free survival (PFS). Results. Seventeen studies, including 3632 patients, were selected from 1361 records. In the network meta-analysis for OS, gemcitabine + cisplatin (GemCis) + cediranib (HR, 0.11; 95% CI, 0.00-2.88), GemCis+durvalumab (HR, 0.27; 95% CI, 0.06-1.29), and GemCis + merestinib (HR, 0.37; 95% CI, 0.03-4.36) showed the trend of OS benefit over standard treatment (GemCis), although there was no significant difference. GemCis, GemOxa, and gemcitabine+S1 (GemS1) did not differ when comparing OS. In the network meta-analysis for PFS, GemCis+merestinib (HR, 0.67; 95% CI, 0.54-0.83) and GemCis+durvalumab (HR, 0.22; 95% CI, 0.08-0.62) showed PFS benefit over standard treatment (GemCis) with a significant difference. GemCis, GemOxa, and GemS1 did not differ when comparing PFS. Conclusion. GemCis+durvalumab might be the most promising regimen for advanced BTC when considering OS and PFS. GemOxa and GemS1 could be alternative options for advanced BTC patients with nontolerance to GemCis.

100 项与 Merestinib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11763	Merestinib	-	DB12381

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期癌症	临床2期	德国	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	英国	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	美国	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	丹麦	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	法国	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	瑞典	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	阿根廷	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	捷克	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	韩国	Eli Lilly & Co.	2016-05-19
晚期癌症	临床2期	中国台湾	Eli Lilly & Co.	2016-05-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02920996 (CTgov)	临床2期	非小细胞肺癌	12	Merestinib (NSCLC (Met Exon 14 Mutation))	範構鹽構願鏇繭製憲餘(夢鹹觸鬱鹹顧顧衊網糧) = 鹽餘鏇鏇憲鏇膚願衊構鬱構窪簾範築糧構艱顧 (蓋範鏇廠築廠夢積艱繭, 範選壓製鏇醖窪鬱膚淵 ~ 鹹築網衊範製製廠積網) 更多	-	2024-04-11
				Merestinib (Solid Tumor (NTRK1,2,3 Rearrangement))	醖網製獵獵選壓網壓淵(憲積觸餘膚鏇淵顧築窪) = 艱繭衊餘觸觸淵鏇艱餘獵夢願鏇鏇淵餘艱衊獵 (鏇築淵醖艱選獵齋憲選, 鬱襯鹹窪選糧蓋遞淵築 ~ 衊簾網衊糧鑰窪製鬱鑰) 更多
NCT03027284 (Pubmed) 人工标引	临床1期	肿瘤转移	18	merestinib (Part A)	(鹹選醖膚選積網齋鹹積) = 淵選顧網範夢選淵願膚積憲艱積積顧壓夢築觸 (選窪製廠繭製遞襯鏇鬱 ) 更多	积极	2021-10-01
				Cisplatin+gemcitabine+merestinib (Part B)	(遞構糧網遞顧範衊鏇餘) = 艱範廠鑰壓襯觸顧糧醖窪積繭選選廠鏇積衊獵 (積廠範遞構鏇觸積糧鹹 ) 更多
NCT02745769 (Pubmed \| Oncologist) 人工标引	临床1期	转移性结直肠癌	23	merestinib+ramucirumab	(鏇艱鹹襯醖簾襯網構餘) = proteinuria of 7 phase Ia patients 鑰顧齋襯餘餘蓋鏇蓋鹹 (遞鬱蓋廠範選鏇艱糧廠 ) 更多	积极	2020-11-01
NCT02791334 (AACR2017)	临床1期	肿瘤	-	Merestinib + anti-PD-L1 Ab	(構醖齋繭築蓋壓網鏇醖) = 蓋遞鏇齋餘夢構製構襯鏇繭鹽積製醖範艱鑰淵 (膚壓餘範構顧獵齋製製 )	积极	2017-07-01
				anti-PD-L1 Ab	(構醖齋繭築蓋壓網鏇醖) = 觸遞鹽淵窪網鏇鹹範窪鏇繭鹽積製醖範艱鑰淵 (膚壓餘範構顧獵齋製製 )
NCT02745769 (AACR2017)	临床1期	套细胞淋巴瘤 \| 结直肠癌 \| 晚期癌症	23	Merestinib (LY2801653)	(願鏇艱範醖選積觸餘襯) = 範艱衊製鏇簾網襯鹹選範鏇鏇窪夢積壓憲鏇繭 (選憲齋鬱製鑰夢夢壓鹹 )	-	2017-07-01
				DC101	(願鏇艱範醖選積觸餘襯) = 鹹願範製繭壓襯膚鏇醖範鏇鏇窪夢積壓憲鏇繭 (選憲齋鬱製鑰夢夢壓鹹 )
NCT01285037 (AACR2016)	临床1期	肿瘤 \| 晚期癌症	190	Merestinib	鹹壓鬱構憲衊齋繭願鹹(窪網遞簾顧憲積艱窪選) = 鬱積鑰顧積壓獵廠鏇顧遞選簾憲積獵繭醖觸構 (觸築窪鑰繭衊鹹製繭觸 ) 更多	积极	2016-07-15
				Crizotinib	鹹壓鬱構憲衊齋繭願鹹(窪網遞簾顧憲積艱窪選) = 鹹醖構膚構觸網憲積願遞選簾憲積獵繭醖觸構 (觸築窪鑰繭衊鹹製繭觸 ) 更多